Comparative Pharmacology
Head-to-head clinical analysis: BRINSUPRI versus ENALAPRILAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRINSUPRI versus ENALAPRILAT.
BRINSUPRI vs ENALAPRILAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRINSUPRI is a novel oral cyclin-dependent kinase (CDK) inhibitor that selectively inhibits CDK4 and CDK6, thereby blocking phosphorylation of the retinoblastoma (Rb) protein and preventing G1-to-S phase cell cycle progression. This induces cell cycle arrest in cancer cells with intact Rb function.
Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and cardiac workload.
4 mg orally once daily, with or without food.
1.25 mg IV over 5 minutes every 6 hours; may increase to 5 mg IV every 6 hours if needed.
None Documented
None Documented
Clinical Note
moderateEnalaprilat + Benzydamine
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Benzydamine."
Clinical Note
moderateEnalaprilat + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Enalaprilat."
Clinical Note
moderateEnalaprilat + Droxicam
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Droxicam."
Clinical Note
moderateEnalaprilat + Loxoprofen
Terminal elimination half-life is approximately 20-30 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may extend to >50 hours, requiring dose adjustment.
Terminal half-life: 35 hours (prolonged in renal impairment; accumulates with CrCl <30 mL/min)
Primarily renal excretion as unchanged drug (70-85%) and minor fecal elimination (10-15%). Biliary excretion accounts for <5%.
Renal: 60-80% unchanged; biliary/fecal: minimal (<10%)
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Enalaprilat is combined with Loxoprofen."